JP2022524391A5 - - Google Patents
Info
- Publication number
- JP2022524391A5 JP2022524391A5 JP2021553767A JP2021553767A JP2022524391A5 JP 2022524391 A5 JP2022524391 A5 JP 2022524391A5 JP 2021553767 A JP2021553767 A JP 2021553767A JP 2021553767 A JP2021553767 A JP 2021553767A JP 2022524391 A5 JP2022524391 A5 JP 2022524391A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- oncolytic virus
- synthetic oncolytic
- synthetic
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024163492A JP2025011109A (ja) | 2019-03-08 | 2024-09-20 | 合成腫瘍溶解性ｌｎｐレプリコンｒｎａおよびがん免疫治療のための使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962815611P | 2019-03-08 | 2019-03-08 | |
| US62/815,611 | 2019-03-08 | ||
| PCT/US2020/013069 WO2020185293A1 (en) | 2019-03-08 | 2020-01-10 | Synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024163492A Division JP2025011109A (ja) | 2019-03-08 | 2024-09-20 | 合成腫瘍溶解性ｌｎｐレプリコンｒｎａおよびがん免疫治療のための使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022524391A JP2022524391A (ja) | 2022-05-02 |
| JP2022524391A5 true JP2022524391A5 (https=) | 2023-01-23 |
| JP7561134B2 JP7561134B2 (ja) | 2024-10-03 |
Family
ID=69526302
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021553767A Active JP7561134B2 (ja) | 2019-03-08 | 2020-01-10 | 合成腫瘍溶解性ｌｎｐレプリコンｒｎａおよびがん免疫治療のための使用 |
| JP2024163492A Pending JP2025011109A (ja) | 2019-03-08 | 2024-09-20 | 合成腫瘍溶解性ｌｎｐレプリコンｒｎａおよびがん免疫治療のための使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024163492A Pending JP2025011109A (ja) | 2019-03-08 | 2024-09-20 | 合成腫瘍溶解性ｌｎｐレプリコンｒｎａおよびがん免疫治療のための使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11717548B2 (https=) |
| EP (2) | EP4729621A2 (https=) |
| JP (2) | JP7561134B2 (https=) |
| KR (2) | KR102889984B1 (https=) |
| CN (1) | CN113966221B (https=) |
| AU (1) | AU2020233788A1 (https=) |
| BR (1) | BR112021017637A8 (https=) |
| CA (1) | CA3132714A1 (https=) |
| CO (1) | CO2021013417A2 (https=) |
| DK (1) | DK3934673T3 (https=) |
| FI (1) | FI3934673T3 (https=) |
| IL (1) | IL285963A (https=) |
| MX (1) | MX2021010808A (https=) |
| MY (1) | MY207334A (https=) |
| PH (1) | PH12021552145A1 (https=) |
| SG (1) | SG11202109514VA (https=) |
| WO (1) | WO2020185293A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113710229B (zh) | 2019-02-25 | 2026-01-06 | 芝加哥大学 | 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物 |
| CN113966221B (zh) * | 2019-03-08 | 2026-03-31 | 麻省理工学院 | 合成溶瘤lnp复制子rna和用于癌症免疫治疗的用途 |
| CZ310613B6 (cs) | 2020-09-23 | 2026-01-28 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Lipidoidy pro transfekci nukleových kyselin a jejich použití |
| CN113509542A (zh) * | 2021-04-20 | 2021-10-19 | 嘉晨西海(杭州)生物技术有限公司 | 一种基于mRNA的表达白介素12针对肿瘤的药物及其制备方法 |
| CZ310443B6 (cs) * | 2021-07-19 | 2025-06-25 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití |
| CN119317430A (zh) | 2022-04-26 | 2025-01-14 | 斯特兰德生物科技公司 | 包含委内瑞拉马脑炎(vee)复制子的脂质纳米颗粒及其用途 |
| CN115227674B (zh) * | 2022-08-05 | 2023-07-04 | 武汉滨会生物科技股份有限公司 | 包封的溶瘤病毒遗传物质及其应用 |
| EP4648781A1 (en) * | 2023-01-12 | 2025-11-19 | Bavarian Nordic A/S | Recombinant modified sarna (vrp) for cancer vaccine |
| EP4687854A2 (en) * | 2023-04-07 | 2026-02-11 | Flagship Labs 114, Inc. | Lipids and lipid-like compounds for therapeutic lipid nanoparticle (lnp) delivery |
| CN118147171B (zh) * | 2024-03-08 | 2024-12-06 | 上海复诺健生物科技有限公司 | 具有增强的外源基因表达水平的自扩增mRNA核酸序列 |
| AU2024299882A1 (en) | 2023-07-25 | 2026-01-08 | Strand Therapeutics Inc. | Polynucleotides comprising a micro rna detargeting sensor and uses thereof |
| WO2025087372A1 (zh) * | 2023-10-27 | 2025-05-01 | 上海元宋生物技术有限公司 | 溶瘤病毒及其用途 |
| CN119479778B (zh) * | 2024-10-16 | 2025-04-25 | 北京悦康科创医药科技股份有限公司 | 一种lnp转染效率预测模型构建方法及装置 |
| CN121081290B (zh) * | 2025-11-12 | 2026-03-10 | 佑嘉(杭州)生物医药科技有限公司 | 一种毛囊靶向递送系统及生发防脱化妆品 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| CA2766907A1 (en) * | 2009-07-06 | 2011-01-13 | Novartis Ag | Self replicating rna molecules and uses thereof |
| MX342608B (es) * | 2010-07-06 | 2016-10-06 | Novartis Ag * | Particulas de suministro similares a viriones para moleculas de arn de autorreplicacion. |
| CA2841047A1 (en) * | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic compositions and uses thereof |
| CA2893762A1 (en) * | 2012-12-03 | 2014-06-12 | Dipu Mohan-Kumar | Ehrlichial invasin for immunization, diagnosis, and cell delivery |
| US10125092B2 (en) | 2014-09-05 | 2018-11-13 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| KR20170074235A (ko) * | 2014-10-31 | 2017-06-29 | 메사추세츠 인스티튜트 오브 테크놀로지 | 면역 세포로의 생체분자의 전달 |
| ES2880103T3 (es) * | 2015-05-21 | 2021-11-23 | Ohio State Innovation Foundation | Derivados de benceno-1, 3, 5-tricarboxamida y usos de los mismos |
| CN113966221B (zh) * | 2019-03-08 | 2026-03-31 | 麻省理工学院 | 合成溶瘤lnp复制子rna和用于癌症免疫治疗的用途 |
| EP4185274A1 (en) * | 2020-07-24 | 2023-05-31 | Strand Therapeutics Inc. | Lipidnanoparticle comprising modified nucleotides |
| US20240140960A1 (en) * | 2021-02-12 | 2024-05-02 | Ohio State Innovation Foundation | Sugar derived lipid nanomaterials and uses thereof |
| CA3225064A1 (en) * | 2021-07-09 | 2023-01-12 | Nathaniel Stephen Wang | Modified eastern equine encephalitis viruses, self-replicating rna constructs, and uses thereof |
| CN117180454A (zh) * | 2022-05-16 | 2023-12-08 | 上海行深生物科技有限公司 | 含有自复制rna分子和脂质纳米颗粒递送载体的组合物及其制备方法 |
-
2020
- 2020-01-10 CN CN202080034343.3A patent/CN113966221B/zh active Active
- 2020-01-10 PH PH1/2021/552145A patent/PH12021552145A1/en unknown
- 2020-01-10 BR BR112021017637A patent/BR112021017637A8/pt unknown
- 2020-01-10 EP EP25227099.6A patent/EP4729621A2/en active Pending
- 2020-01-10 DK DK20704372.0T patent/DK3934673T3/da active
- 2020-01-10 KR KR1020217032460A patent/KR102889984B1/ko active Active
- 2020-01-10 CA CA3132714A patent/CA3132714A1/en active Pending
- 2020-01-10 AU AU2020233788A patent/AU2020233788A1/en active Pending
- 2020-01-10 JP JP2021553767A patent/JP7561134B2/ja active Active
- 2020-01-10 MX MX2021010808A patent/MX2021010808A/es unknown
- 2020-01-10 EP EP20704372.0A patent/EP3934673B1/en active Active
- 2020-01-10 WO PCT/US2020/013069 patent/WO2020185293A1/en not_active Ceased
- 2020-01-10 MY MYPI2021005045A patent/MY207334A/en unknown
- 2020-01-10 FI FIEP20704372.0T patent/FI3934673T3/fi active
- 2020-01-10 KR KR1020257038746A patent/KR20250171410A/ko active Pending
- 2020-01-10 SG SG11202109514VA patent/SG11202109514VA/en unknown
- 2020-01-10 US US16/739,407 patent/US11717548B2/en active Active
-
2021
- 2021-08-30 IL IL285963A patent/IL285963A/en unknown
- 2021-10-07 CO CONC2021/0013417A patent/CO2021013417A2/es unknown
-
2023
- 2023-06-14 US US18/334,449 patent/US12383589B2/en active Active
-
2024
- 2024-09-20 JP JP2024163492A patent/JP2025011109A/ja active Pending
-
2025
- 2025-07-09 US US19/264,067 patent/US20260061013A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022524391A5 (https=) | ||
| FI3934673T3 (fi) | Synteettinen onkolyyttinen lnp-replikoni-rna ja sen käyttöjä syövän immunoterapiaan | |
| Liu et al. | Alginic acid-coated chitosan nanoparticles loaded with legumain DNA vaccine: effect against breast cancer in mice | |
| Yaremenko et al. | Clinical advances of mRNA vaccines for cancer immunotherapy | |
| Parato et al. | Recent progress in the battle between oncolytic viruses and tumours | |
| Nadeem et al. | A Virus‐Spike Tumor‐Activatable Pyroptotic Agent | |
| Gao et al. | Functionalized DMP-039 hybrid nanoparticle as a novel mRNA vector for efficient cancer suicide gene therapy | |
| Malla et al. | mRNA vaccines and their delivery strategies: a journey from infectious diseases to cancer | |
| Ladak et al. | The current Landscape of mRNA vaccines against viruses and cancer–a mini review | |
| Strods et al. | Preparation by alkaline treatment and detailed characterisation of empty hepatitis B virus core particles for vaccine and gene therapy applications | |
| Touchefeu et al. | gene therapy, recent developments and future prospects in gastrointestinal oncology | |
| Bauso et al. | Biological activity of natural and synthetic peptides as anticancer agents | |
| JP2023535225A5 (https=) | ||
| Bahreyni et al. | A combination of genetically engineered oncolytic virus and melittin-CpG for cancer viro-chemo-immunotherapy | |
| Zhang et al. | Self‐Oxygenated biomimetic nanozyme for tumor catalytic immunotherapy | |
| Hromic-Jahjefendic et al. | Viral vector-based melanoma gene therapy | |
| Vasilevska et al. | Semliki Forest virus biodistribution in tumor-free and 4T1 mammary tumor-bearing mice: a comparison of transgene delivery by recombinant virus particles and naked RNA replicon | |
| Martinis et al. | Cancer vaccines: from the state of the art to the most promising frontiers in the treatment of colorectal cancer | |
| Newman et al. | Infection: a cause of and cure for cancer | |
| Ghazizadeh et al. | Advances in cancer nanovaccines: a focus on colorectal cancer | |
| JP2024503000A5 (https=) | ||
| Adesokan et al. | SARS-CoV-2: vaccinology and emerging therapeutics; challenges and future developments | |
| Abdessalem et al. | Research advancements in nanoparticles and cell-based drug delivery systems for the targeted killing of cancer cells | |
| Abdel-Rashid et al. | Fabrication of gold nanoparticles in absence of surfactant as in vitro carrier of plasmid DNA | |
| Pierrefite-Carle et al. | Subcutaneous or intrahepatic injection of suicide gene modified tumour cells induces a systemic antitumour response in a metastatic model of colon carcinoma in rats |